| Literature DB >> 33758661 |
Yoshiaki Fujii1, Kenji Kobayashi1, Syo Kimura1, Shuhei Uehara1, Hirotaka Miyai1, Shuji Takiguchi2.
Abstract
The optimal surgical indications for small rectal neuroendocrine tumors (NETs) are controversial. Generally, treatment guidelines for rectal NETs >2 cm or with potential lymph node (LN) metastasis recommend formal oncologic low anterior resection (LAR) with total mesorectal excision (TME). However, rectal NETs have the potential to metastasize to the lateral lymph nodes (LLNs). To the best of our knowledge, there are no detailed reports in English on LLN metastasis from rectal NETs. A 47-year-old man diagnosed with a rectal NET underwent endoscopic submucosal dissection (ESD). The pathological diagnosis was NET G1. The tumor was 10 mm in diameter, and the tumor depth reached the submucosal layer. A period of 3 years after ESD, the patient was diagnosed with LN metastasis in the mesorectum and LLN metastasis on the left side from the NET. Robotic TME and bilateral LN dissection were performed. The pathological findings indicated that two of the 18 LNs in the mesorectum were metastatic, and all the LLNs on the left side were negative. In contrast, 1 of the 6 LLNs on the right side was metastatic. Early-stage rectal NETs can metastasize to the LLNs, and it is very difficult to detect LLN metastasis based on size alone. TME alone may be insufficient to treat rectal NETs, and additional LLN dissection may be an important treatment strategy. However, it is increasingly difficult to determine the surgical indications for optimally timed LLN dissection. Copyright: © Fujii et al.Entities:
Keywords: lateral lymph node dissection; metastasis; neuroendocrine tumor; rectum
Year: 2021 PMID: 33758661 PMCID: PMC7947950 DOI: 10.3892/mco.2021.2242
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450
Figure 1(A) Colonoscopy revealed a hemispheric submucosal tumor that was 7 mm in diameter in the lower rectum without central depression or ulceration. (B) Colonoscopy revealed a scar in the lower rectum after ESD, and the biopsy detected no evidence of local recurrence. ESD, endoscopic submucosal dissection.
Figure 2Histopathological findings of the resected specimen (primary tumor). (A) Macroscopic findings of the resected specimen indicated that the primary tumor was 10 mm in diameter. (B) Hematoxylin and eosin staining showed that the tumor cells spread in a rosette-like pattern (magnification, x4). (C) The Ki-67 index was 1.7% (magnification, x400). (D) Immunohistochemical staining for synaptophysin was positive (magnification, x400).
Figure 3Preoperative imaging examinations performed 3 years after ESD. (A) Contrast-enhanced CT and (B) T2-weighted axial MRI revealed lymph node enlargement in the mesorectum and on the left side of the lateral pelvic space (red circle). The maximum lymph node size in the mesorectum was 12.1 mm and that in the left obturator space was 10 mm. (C) 68Ga-DOTATOC PET imaging revealed high 68Ga-DOTATOC uptake in the mesorectum and no uptake in either side of the lateral pelvic space. ESD, endoscopic submucosal dissection.
Figure 4Histopathological findings of the resected specimen (metastatic LLN on the right side). (A) Hematoxylin and eosin staining showed that the diameter of the metastatic LLN on the right side was 7 mm. (B) Immunohistochemical staining for chromogranin A was negative (magnification, x400). (C) The Ki-67 index was 2.0% (magnification, x400). (D) Immunohistochemical staining for synaptophysin was positive (magnification, x400). LLN, lateral lymph nodes.
Reported resection cases of rectal NETs with LLN metastasis.
| Case no. | First author, year | Age/sex | Tumor size, mm | Depth of invasion | Lymphovascular invasion | Number/maximum size (metastatic LLN), mm | Metastatic LN in the mesorectum | Prognosis | (Refs.) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Tokoro | 53/F | 20 | Muscularis propria | + | 2/20 | + | 47 m/alive | ( |
| 2 | Yamada | 79/F | 8 | Muscularis propria | - | 1/150 | - | Unknown | ( |
| 3 | Yamaguchi | 44/M | 16 | Submucosa | + | 1/15 | - | 39 m/alive | ( |
| 4 | Oi | 46/M | 12 | Submucosa | - | 2/21 | - | 48 m/alive | ( |
| 5 | Ohno | 53/F | 10 | Submucosa | + | 1/11 | + | 3 m/alive | ( |
| 6 | Miyake | 44/M | 12 | Submucosa | + | 3/55 | + | 19 m/alive | ( |
| 7 | Beppu | 59/M | 7 | Submucosa | + | 1/7 | - | 36 m/alive | ( |
| 8 | The current study, 2020 | 46/M | 10 | Submucosa | + | 1/7 | - | 12 m/alive |
F, female; M, male; LLN, lateral lymph nodes; LN, lymph node; NET, neuroendocrine tumors; m, months.
Reported resection cases of LLN recurrence from rectal NETs.
| Case no. | First author, year | Age/sex | Tumor size, mm | Depth of invasion | Lymphovascular invasion | Number/maximum size (metastatic LLN), mm | Metastatic LN in the mesorectum | Recurrence interval (LLNR) | Prognosis | (Refs.) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ichinokawa | 57/F | 35 | Muscularis propria | + | 1/25 | - | 18 m | 44 m/alive | ( |
| 2 | Nakamoto | 70/M | 20 | Submucosa | Unknown | 1/unknown | + | 50 m | 72 m/alive | ( |
| 3 | Umeda | 66/M | 7 | Submucosa | - | 1/23 | - | 276 m | 288 m/alive | ( |
| 4 | Tokumaru | 55/M | 14 | Submucosa | - | 1/14 | - | 54 m | 96 m/alive | ( |
F, female; M, male; LLN, lateral lymph nodes; NET, neuroendocrine tumors; LN, lymph node; LLNR, lateral lymph node recurrence; m, months.